Beth Eaby-Sandy, MSN, CRNP, OCN®
University of Pennsylvania
The scope of knowledge and skills required to safely manage oncology patients today is daunting. Personalized medicine is becoming the standard of care as new molecular/genetic testing becomes available. This activity will provide advanced practitioners with an overview of histologic and molecular differentiation in the diagnosis and staging of non–small cell lung cancer, and how to apply that knowledge to the ordering and interpretation of diagnostic and molecular testing.
Management of Patients With Cytotoxic Chemotherapy
Targeted Therapies in Advanced Non–Small Cell Lung Cancer
Management of Patients Treated With Immunotherapy
Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer
What is the role of EGFR mutations in patients with NSCLC?
What is T790m and describe its role in drug resistance?
What is ALK and how does it impact the treatment of NSCLC?
What should advanced practitioners know about the side effect profiles of targeted treatments for NSCLC?
What should pharmacists know about combining treatment agents for patients with NSCLC?
Bone Marrow Biopsy Demonstration Video
Do you want to access this activity for credit?